"name","instanceType","uuid:ID","id","description","text","label"
"OBJ1","Objective","f2984fc9-7bf5-4c98-9845-553a14209ea3","Objective_1","Main objective","To determine if there is a statistically significant relationship (overall Type 1 erroralpha=0.05) between the change in both the ADAS-Cog (11) and CIBIC+ scores, and drug dose (0, 50 cm2 [54 mg], and 75 cm2 [81 mg]).",""
"OBJ2","Objective","13657e05-e363-4052-980c-be163156f050","Objective_2","Safety","To document the safety profile of the xanomeline TTS.",""
"OBJ3","Objective","1c775832-0aa3-4321-bcc1-eac574663d1f","Objective_3","Behaviour","To assess the dose-dependent improvement in behavior. Improved scores on the Revised Neuropsychiatric Inventory (NPI-X) will indicate improvement in these
areas.",""
"OBJ4","Objective","d14a3e0d-92e5-423c-be97-62d4622fa5f8","Objective_4","","To assess the dose-dependent improvements in activities of daily living. Improved scores on the Disability Assessment for Dementia (DAD) will indicate improvement in these areas (see Attachment LZZT.5).",""
"OBJ5","Objective","4a555a50-495f-4f6c-8785-71a833d21822","Objective_5","","To assess the dose-dependent improvements in an extended assessment of cognition that integrates attention/concentration tasks. The Alzheimer's Disease Assessment Scale-14 item Cognitive Subscale, hereafter referred to as ADAS-Cog (14), will be used for this assessment (see Attachment LZZT.2).",""
"OBJ6","Objective","ce57825f-3665-4f2b-bb6e-872ae5df07b4","Objective_6","","To assess the treatment response as a function of Apo E genotype.",""
